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Objective: To describe the characteristics of individuals with early sustained recovery following ﬁrst episode psy-
chosis.
Methods: Individuals with a ﬁrst episode psychosis were followed-up for ten years. Comparisons were made be-
tween those with Early Sustained Recovery and those with Other Course types.
Results:Of 345 individuals, n= 43 (12.5%) had Early Sustained Recovery. Theywere more likely than those with
Other Course types to be female (OR= 2.45; 95% CI: 1.25–4.81); employed (OR= 2.39; 95% CI: 1.22–4.69); in a
relationship (OR= 2.68; 95% CI: 1.35–5.32); have a short DUP (OR= 2.86; 95% CI: 1.37–5.88); and have a diag-
nosis other than schizophrenia, particularly mania (OR = 6.39; 95% CI: 2.52–16.18) or brief psychosis (OR =
3.64; 95% CI: 1.10–12.10).
Conclusions: Sustained recovery from ﬁrst episode psychosis occurs in a minority.










A majority of individuals with a ﬁrst episode psychosis experience
symptom remissionwithin theﬁrst year following contactwith services
(Wiersma et al., 1998; Robinson et al., 1999; Morgan et al., 2014). For
some, this remission extends into sustained recovery with no subse-
quent psychotic episodes. For others, therewill be relapse of symptoms.
This can occur whether on treatment or not, though non-adherence
with medication is strongly associated with relapse (Alvarez-Jimenez
et al., 2012; Robinson et al., 1999). Other factors which have been iden-
tiﬁed in meta-analyses to be associated with relapse include premorbid
adjustment and ongoing substance use, with some evidence for non-af-
fective symptoms (Alvarez-Jimenez et al., 2012).
A related, but distinct, issue is whether there are useful predictors of
sustained recovery following ﬁrst episode psychosis. Alvarez-Jimenez et
al. (2011) found that 16%of individuals aged 16–30yearswith aﬁrst ep-
isode psychosis experienced only a single psychotic episode, deﬁned as
an index episode which did not exceed 12months' duration, no further
episodes, and being “virtually symptom-free and showing their
premorbid personality” for a minimum of four weeks over a mean 7.5-
year follow-up. Predictors of a single psychotic episode included short
duration of untreated psychosis (DUP). We used the comprehensive
dataset from the AESOP-10 longitudinal follow-up study of ﬁrst episode
psychosis in order to examine this question in a sample aged 18–
64 years. We identiﬁed all individuals who achieved early sustained re-
covery.We aimed,ﬁrst, to compare their demographic and clinical char-
acteristics with those with other course types and, second, to describe
patterns of medication use over follow-up in those with early sustained
recovery.
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Table 1
Demographic and clinical characteristics, and outcomemeasures of the Early Sustained Recovery andOther Course type individuals, showingunadjusted and adjusted odds ratios (OR) and
95% conﬁdence intervals (CI).
Other Course type (n = 302)
no (%) or mean (SD)
Early Sustained
Recovery (n = 43)
Unadj. OR 95% CI p Adj. OR (1)a 95% CI p
Demographic
Study Centre
London 188 (62.3) 27 (62.8) 1.00 – – 1.00 – –
Nottingham 114 (37.7) 16 (37.2) 0.98 0.51–1.89 0.95 0.98 0.50–1.93 0.96
Sex
Men 173 (57.3) 15 (34.9) 1.00 – – 1.00 – –
Women 129 (42.7) 28 (65.1) 2.50 1.28–4.88 0.007 2.45 1.25–4.81 0.009
Age
16–29 158 (52.3) 20 (46.5) 1.00 – – 1.00 – –
30–64 144 (47.7) 23 (53.5) 1.26 0.67–2.39 0.48 1.15 0.60–2.21 0.67
Ethnicity
White British 125 (41.4) 21 (48.8) 1.00 – – 1.00 – –
Other 177 (58.6) 22 (51.2) 0.74 0.39–1.40 0.36 0.72 0.37–1.39 0.33
Relationship statusb
Single 217 (75.3) 21 (51.2) 1.00 – – 1.00 – –
In a relationship 71 (24.7) 20 (48.8) 2.91 1.49–5.68 0.002 2.68 1.35–5.32 0.005
Employmentc
Unemployed 179 (60.3) 16 (37.2) 1.00 – – 1.00 – –
Employed 118 (39.7) 27 (62.8) 2.56 1.32–4.96 0.005 2.39 1.22–4.69 0.01
Educationd
University 34 (11.7) 5 (11.6) 1.00 – – 1.00 – –
Further 81 (27.9) 13 (30.2) 1.09 0.36–3.30 0.88 1.31 0.43–4.04 0.64
GCSE 75 (25.9) 13 (30.2) 1.18 0.39–3.57 0.77 1.48 0.48–4.60 0.49
No qualiﬁcations 100 (34.5) 12 (27.9) 0.82 0.27–2.49 0.72 0.95 0.31–2.93 0.92
Clinical
Diagnosis
Schizophrenia 145 (48.0) 9 (20.9) 1.00 – – 1.00 – –
Mania 32 (10.6) 15 (34.9) 7.55 3.04–18.78 0.001 6.39 2.52–16.18 0.001
Depression 44 (14.6) 7 (16.3) 2.56 0.90–7.28 0.08 2.17 0.74–6.34 0.16
Schizoaffective 14 (4.6) 3 (7.0) 3.45 0.84–14.24 0.09 3.18 0.76–13.26 0.11
Brief 20 (6.6) 5 (11.6) 4.03 1.23–13.23 0.02 3.64 1.10–12.10 0.04
Other 47 (15.6) 4 (9.3) 1.37 0.40–4.66 0.61 1.32 0.39–4.50 0.66
Dimensionsg
Reality distortion 3.8 (2.8) 2.9 (2.5) 0.87 0.76–1.00 0.05 0.88 0.76–1.01 0.07
Negative 1.3 (1.9) 0.5 (1.2) 0.70 0.51–0.95 0.02 0.72 0.54–0.98 0.04
Disorganised 1.3 (1.9) 0.5 (1.2) 0.86 0.57–1.29 0.46 0.88 0.58–1.34 0.55
Mania 1.5 (2.5) 2.4 (3.1) 1.12 1.00–1.25 0.05 1.10 0.98–1.23 0.12
Depression 1.2 (1.8) 1.6 (1.8) 1.11 0.94–1.33 0.23 1.10 0.92–1.31 0.30
Mode of onsete
Acute 109 (41.6) 23 (57.5) 1.00 – – 1.00 – –
Insidious 153 (58.4) 17 (42.5) 0.53 0.27–1.03 0.06 0.59 0.30–1.19 0.14
DUPf
Long 151 (51.9) 11 (25.6) 1.00 – – 1.00 – –
Short 140 (48.1) 32 (74.4) 3.13 1.49–6.25 0.002 2.86 1.37–5.88 0.005
Symptom severityg 8.5 (4.6) 8.0 (4.8) 0.97 0.90–1.05 0.50 0.97 0.90–1.05 0.49
Mode of admission
Community treatment 94 (31.1) 14 (32.6) 1.00 – – 1.00 – –
Voluntary admission 96 (31.8) 13 (30.2) 0.91 0.41–2.04 0.82 0.81 0.36–1.85 0.62
Compulsory admission 112 (37.1) 16 (37.2) 0.96 0.45–2.06 0.92 0.86 0.39–1.88 0.70
Lifetime alcohol useh
No misuse/dependence 233 (82.6) 38 (92.7) 1.00 – – 1.00 – –
Misuse/dependence 49 (17.4) 3 (7.3) 0.38 0.11–1.27 0.11 0.47 0.14–1.59 0.22
Lifetime illicit drug usei
No misuse/dependence 217 (77.8) 31 (79.5) 1.00 – – 1.00 – –
Misuse/dependence 62 (22.2) 8 (20.5) 0.90 0.40–2.08 0.81 1.30 0.53–3.23 0.57
Outcomes
Treatment at 12 monthsj
On treatment 128 (50.8) 29 (85.3) 1.00
Not on treatment 124 (49.2) 5 (14.7) 0.17 0.06–0.45 0.001 0.18 0.07–0.48 0.001
Full recovery at follow upk
Clinical only 26 (11.3) 16 (45.7) 1.00
Clinical and functional 205 (88.7) 19 (54.3) 0.15 0.07–0.33 0.001 0.14 0.06–0.32 0.001
Bold indicates signiﬁcance at p N 0.05 level.
a Adjusted for, as appropriate, sex and age (as continuous variable).
b Missing, 16.
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2. Materials and methods
2.1. Setting
AESOP-10 is a follow-up at approximately 10 years of a cohort of in-
dividuals with a ﬁrst episode of psychosis identiﬁed in the South East
London and Nottingham centres of the AESOP study (Kirkbride et al.,
2006). Full methods are detailed in Morgan et al. (2014).
2.2. Cases
Inclusion criteria: aged 16–64 yearswith a ﬁrst episode of psychosis;
resident within the study catchment areas. Exclusion criteria: evidence
of psychotic symptoms precipitated by an organic cause; transient psy-
chotic symptoms resulting from acute intoxication as deﬁned by ICD–10
(WHO, 1993); previous contacts with mental health services for psy-
chosis; moderate/severe learning difﬁculties, or IQ b 50 (WHO, 1993).
2.3. Follow-up
Cases were followed-up ten years after ﬁrst contact with mental
health services. Of 532 incident cases, 458 remained after removing
those who had died, emigrated, or been excluded (Morgan et al.,




Clinical and demographic data were collected from interview, infor-
mants, and clinical records. The SCAN version 2 (WHO, 1992) was used
to assess symptom presence and severity. This was used in conjunction
with other clinical information (excluding diagnosis) to assign ICD-10
(WHO, 1993) psychotic diagnoses within research-team consensus
meetings. The Personal and Psychiatric History Schedule (WHO, 1996)
was used to determineDUP, deﬁned as the period fromonset of psycho-
sis to ﬁrst contact with mental health services. Onset of psychosis was
deﬁned as the presence for one week or more of psychotic symptoms
(Morgan et al., 2006).
2.4.2. Follow-up
TheWHOLife Chart Schedule (Harrison et al., 2001)was used to col-
late information at follow-up. It comprises four main areas: symptoms;
treatment; residence; andwork. It was adapted to include additional in-
formation on service use, including use of prescribed medication.
Course of illness was categorised as follows: Early Sustained Recovery
(remission within six months and no further psychotic episodes over
10-year follow-up) and Other Course comprising episodic (no episode
longer than six months' duration), continuous (no remission longer
than six months' duration) and intermediate (neither episodic nor
continuous).
2.5. Statistical analyses
Conducted using SPSS Statistics Version 22 (IBM 2013). Categorical
variables were analysed using logistic regression. Comparisons were
made between the Early Sustained Recovery and Other Course groups,
adjusting for age and sex.
3. Results
3.1. Demographic and clinical characteristics
Of the 458 baseline cases, useable information on clinical course and
outcomewas available for 345 (75.3% of 458): Early Sustained Recovery
(ESR) (n = 43; 12.5%) and Other Course (OC) (n = 302; 87.5%). OC
comprised episodic n=69 (20%), continuous n=80 (23.2%), and inter-
mediate n = 153 (44.3%). Median age at baseline for the total sample
was 29.0 (range 16–62) (mean = 30.5 ± 10.2(SD)) years. Median age
for the ESR group was 30.0 (range 17–56) (mean = 31.8 ± 10.5(SD))
years, and for the OC group 29.0 (range 16–62) (mean = 30.4 ± 10.1
(SD)) years (MWU= 5994.5, p = 0.42).
ESR individuals were predominantly women (65.1%) and employed
(62.8%) (Table 1). They weremore likely than OC to be in a relationship
(OR = 2.68; 95% CI: 1.35–5.32) and to have a short DUP (OR = 2.86;
95%CI: 1.37–5.88). Theyweremore likely at baseline tohave a diagnosis
other than schizophrenia, with the evidence being most robust for
mania (OR = 2.39; 95% CI: 1.22–4.69) and for brief psychosis (OR =
2.39; 95% CI: 1.22–4.69). ESR individuals had fewer negative symptoms
(OR= 0.72; 95% CI: 0.54–0.98) and, more tentatively, fewer symptoms
of reality distortion (OR 0.88; 95% CI0.76–1.01) and more manic symp-
toms (OR 1.10; 95% CI 0.98–1.23). There was no strong evidence of dif-
ferences between groups in age, study centre, ethnicity, educational
level attained,mode of onset, symptom severity at ﬁrst episode psycho-
sis, non-hospitalisation atﬁrst episode psychosis, compulsory treatment
atﬁrst episode psychosis, or lifetime alcohol or illicit drugmisuse (Table
1). A logistic regression model of ESR on gender and diagnosis demon-
strated that gender was no longer a signiﬁcant predictor, while mania
and brief psychoses each signiﬁcantly predicted ESR (Table 2).
3.2. Medication use during follow-up
ESR individuals were less likely to be taking treatment at 12months
post-ﬁrst episode psychosis (OR = 0.18; 95% CI: 0.07–0.48). They were
more likely to be in full functional recovery at follow-up (OR = 7.17;
95% CI: 3.17–16.18) (Table 1). Patterns of taking treatment differed be-
tween the groups (X2=98.61, p=0.001) (Table 3): 95% of ESR individ-
uals took antipsychotic treatment at the time of ﬁrst episode psychosis;
17.9% restarted treatment at some later point during the follow-up; and
74.4% stopped and never restarted. The median duration of treatment
was 53 days (SD: 276.7; range: 0–1393; mean: 154.2). Around 20%
took treatment for 14 days or less. Only one individual took treatment
throughout follow-up.
Treatment during follow-up for conditions other than psychosis was
received by 19 (44.2%) for hypomania with or without depression; 7
(16.3%) depression; 1 post-traumatic stress disorder; and 1 alcohol
abuse. A further 7 (16.3%) reported periods of depression with or with-
out anxiety for which they did not seek treatment. Nine (20.9%) made
attempt(s) to kill (7) or harm themselves (2) over the follow-up period,
based on the individual's reported intent.
4. Discussion
One in eight individuals with ﬁrst episode of psychosis recovered
early and never experienced a recurrence over ten-year follow-up.
This is important and relevant to clinical decision-making following
ﬁrst episode psychosis, when a key question raised is: what is the risk
of relapse (or continued symptoms) following a single episode of
Table 2
Logistic regression model of early sustained recovery on gender and diagnosis.
Independent variable Odds ratio ± 95% CIa p
Female gender 1.91 (0.95–3.84) 0.07
Diagnosis 0.03
Mania 6.38 (2.52–16.14) b0.001
Depression 2.25 (0.78–6.48) 0.13
Schizoaffective 3.24 (0.78–13.51) 0.11
Brief 3.67 (1.11–12.19) 0.03
Other 1.32 (0.39–4.52) 0.65
Bold indicates signiﬁcance at p N 0.05 level.
a Odds ratios and 95% Conﬁdence Intervals for each variable as an independent pre-
dictor of early sustained recovery.
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psychosis? Our ﬁndings suggest around 88% (or 7 in 8). Early sustained
recovery was more common among women of any age, those with a
short DUP, those with a diagnosis other than schizophrenia, and those
who had good premorbid function, as evidenced by being employed
and in a relationship. Half the group had an affective psychosis, in keep-
ing with evidence that affective disorders generally follow more
favourable trajectories than non-affective disorders (Bottlender et al.,
2010). Of note, in the logistic regressionmodel of early sustained recov-
ery on gender and diagnosis, the effect of genderwas explained by diag-
nosis, with mania and brief psychoses signiﬁcantly predicting early
sustained recovery.
Only 15% of individuals with early sustained recovery were taking
treatment by 12 months post-ﬁrst episode psychosis, despite 95%
being initiated on an antipsychotic. These data pertain to a second clin-
ical question: for how long should antipsychotic treatment be main-
tained? Some argue that, “treatment discontinuation should not be a
part of routine clinical care” (Emsley et al., 2013). Others make the
case that there is little evidence that antipsychotic medications reduce
or eliminate psychosis (Harrow et al., 2014): over 20-year follow-up
N70% of schizophrenia patients continuously prescribed antipsychotics
experienced psychotic symptoms at the majority of follow-up assess-
ments. Further concerns associated with long-term treatment include
its potential cumulative detrimental effects on physical health and
brain structure (Murray et al., 2016).
Only one individual with early sustained recovery did not attempt a
trial off antipsychotic treatment, that is, remained on treatment
throughout follow-up. It is clear, however, that in a minority there is
sustained recoverywithout treatment: 74.4% of our sample stopped an-
tipsychotic treatment and never restarted. There is a known paradox in
discontinuation studies: while up to 50% of patients with schizophrenia
relapse by 6–10 months following discontinuation, those who remain
stable during the ﬁrst few months post-discontinuation are much less
likely to relapse subsequently (Viguera et al., 1997). This is made
more likely where withdrawal from treatment is gradual rather than
abrupt (Viguera et al., 1997). We argue, therefore, that where an indi-
vidual has sustained a period of remission, reduction and/or gradual dis-
continuation of antipsychotic treatment are legitimate management
options, albeit with signiﬁcant associated risks. If low-grade symptoms
recur, treatment can be reintroduced. Indeed, this is the most likely ex-
planation for our ﬁnding that seven (18%) individuals with early
sustained recovery restarted treatment at some later point during the
follow-up despite never again meeting criteria for a further psychotic
episode.
Finally, regular monitoring should remain a mainstay of treatment.
Despite achieving sustained recovery from psychosis, 40% of the indi-
viduals with early sustained recovery experienced considerable psychi-
atric morbidity over 8-year follow-up, with over 40% receiving
treatment (not antipsychotic) for other conditions, and 20% self-
harming or attempting suicide.
In conclusion, our naturalistic study of outcomes following ﬁrst epi-
sode psychosis provides evidence that in a minority there is early
sustained recovery. This is more likely in women of all ages, those
with good premorbid adjustment, and those with brief or affective psy-
chotic symptoms. Due consideration should be given to the risks and
beneﬁts of continued treatment in those with sustained symptomatic
remission.
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